Holen Sie sich die Stockscreener-App
8.07
6.32%
0.48
Schlusskurs vom Vortag:
$7.59
Offen:
$7.41
24-Stunden-Volumen:
240.08K
Relative Volume:
0.65
Marktkapitalisierung:
$172.23M
Einnahmen:
$155.00K
Nettoeinkommen (Verlust:
$-30.01M
KGV:
-4.8323
EPS:
-1.67
Netto-Cashflow:
$-11.98M
1W Leistung:
+4.40%
1M Leistung:
+0.50%
6M Leistung:
+51.98%
1J Leistung:
-26.30%
1-Tages-Spanne:
$7.41
$8.16
1-Wochen-Bereich:
$7.07
$8.16
52-Wochen-Spanne:
$4.32
$12.72
Inmune Bio Inc Stock (INMB) Company Profile
Firmenname
Inmune Bio Inc
Sektor
Branche
Telefon
(858) 964-3720
Adresse
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Vergleichen Sie INMB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INMB
Inmune Bio Inc
|
8.07 | 172.23M | 155.00K | -30.01M | -11.98M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-10-21 | Eingeleitet | Alliance Global Partners | Buy |
| 2024-09-27 | Eingeleitet | Raymond James | Outperform |
| 2024-08-22 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-06-01 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-05-24 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-07-07 | Bestätigt | Maxim Group | Buy |
| 2021-04-21 | Eingeleitet | B. Riley Securities | Buy |
| 2021-01-22 | Bestätigt | Maxim Group | Buy |
| 2020-09-01 | Eingeleitet | BTIG Research | Buy |
| 2020-07-15 | Bestätigt | H.C. Wainwright | Buy |
Alle ansehen
Inmune Bio Inc Aktie (INMB) Neueste Nachrichten
INmune Bio Presents MINDFuL Trial Data At AD/PD 2025 - Nasdaq
INmune Bio Presents Baseline Data From MINDFuL Phase II Trial In Early Alzheimer's Disease - Nasdaq
INmune Bio presents early Alzheimer’s trial data at AD/PD - Investing.com
INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study - The Manila Times
INmune Bio presents early Alzheimer’s trial data at AD/PD By Investing.com - Investing.com UK
Promising Patient Profile Emerges in Major Alzheimer's Drug Trial: 69% Carry Key Risk Gene - Stock Titan
Raymond James maintains INmune Bio stock with $23 target By Investing.com - Investing.com Australia
Raymond James maintains INmune Bio stock with $23 target - Investing.com India
Raymond James Financial Inc. Takes Position in INmune Bio, Inc. (NASDAQ:INMB) - Defense World
INmune Bio anticipates Alzheimer's trial results within 100 days while advancing therapeutic platforms - MSN
INmune Bio, Inc. (NASDAQ:INMB) Q4 2024 Earnings Call Transcript - Insider Monkey
INmune Bio (INMB) Eyes Landmark Developments in 2024 Amid Rising Financial Commitments - GuruFocus
INmune Bio Inc (INMB) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance
INmune Bio Inc (INMB) Q4 2024 Earnings Call Highlights: Strategi - GuruFocus.com
INmune Bio Reports 2024 Financial Results and Clinical Progress - TipRanks
Earnings call transcript: INmune Bio’s Q4 2024 results highlight innovation focus By Investing.com - Investing.com South Africa
Earnings call transcript: INmune Bio’s Q4 2024 results highlight innovation focus - Investing.com India
INmune Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
INmune Bio Inc Reports Q4 EPS of -$0.53 and Revenue of $0.01 Mil - GuruFocus.com
INMUNE BIO Earnings Results: $INMB Reports Quarterly Earnings - Nasdaq
INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update - TradingView
INmune Bio's Triple Threat: Alzheimer's Trial Fully Enrolled, FDA Designations Secured - Stock Titan
(INMB) On The My Stocks Page - news.stocktradersdaily.com
What to Expect from INmune Bio's Earnings - Benzinga
INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025 - The Manila Times
INmune Bio Sets Key Q4 Earnings Date: Critical Updates Expected for Clinical Pipeline - Stock Titan
Undercovered Dozen: INmune Bio, Primerica, First Quantum, Pinnacle West + - Seeking Alpha
INmune Bio (INMB) Projected to Post Quarterly Earnings on Thursday - Defense World
INmune Bio: CORDStrom Is A Game-Changer, As Investors Await Alzheimer's Results (INMB) - Seeking Alpha
Analysts Set INmune Bio, Inc. (NASDAQ:INMB) Target Price at $22.80 - Defense World
INmune Bio, Inc. (NASDAQ:INMB) Position Lifted by Rhumbline Advisers - Defense World
Protalix BioTherapeutics (NYSE:PLX) and INmune Bio (NASDAQ:INMB) Head-To-Head Review - The AM Reporter
(INMB) Investment Analysis - Stock Traders Daily
INmune Bio Reports Promising Phase I/II Trial Results - TipRanks
PMGC Holdings Ends License Agreement with INmune Bio By Investing.com - Investing.com South Africa
PMGC Holdings Ends License Agreement with INmune Bio - Investing.com
Why INmune Bio, Inc. (INMB) is Skyrocketing So Far in 2025 - MSN
Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
Is INmune Bio (NASDAQ:INMB) A Risky Investment? - Simply Wall St
INmune Delivers Impressive 100% Gain In Just 3 MonthsIs There More Room To Run? - RTTNews
Learn to Evaluate (INMB) using the Charts - Stock Traders Daily
INmune Bio, Inc. to Host Earnings Call - ACCESS Newswire
INmune Bio, Inc. (NASDAQ:INMB) most popular amongst individual investors who own 36% of the shares, institutions hold 28% - Yahoo Finance
INmune Bio, Inc. (NASDAQ:INMB) Receives Consensus Rating of “Buy” from Brokerages - Armenian Reporter
INmune Bio, Inc. (NASDAQ:INMB) Short Interest Update - MarketBeat
INmune Bio, Inc. (NASDAQ:INMB) Sees Significant Growth in Short Interest - Defense World
INmune Bio, Inc. (NASDAQ:INMB) Receives $21.00 Consensus Price Target from Analysts - Defense World
INmune Bio (NASDAQ:INMB) Stock Price Expected to Rise, Maxim Group Analyst Says - MarketBeat
INmune Bio, Inc. (NASDAQ:INMB) Receives $21.00 Consensus Price Target from Brokerages - Defense World
INmune Bio, Inc. (NASDAQ:INMB) Receives $21.00 Average Price Target from Brokerages - MarketBeat
Finanzdaten der Inmune Bio Inc-Aktie (INMB)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):